It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Sanofi, a global healthcare and pharmaceutical company, developed Beyfortus, a new immunisation for babies against Respiratory Syncytial Virus (RSV), launching it internationally and taking an ...

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), ...

driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was ...

Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.

Dr Reddy's Laboratories has partnered with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in ...

Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.